BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250320T190000
DTEND;TZID=Africa/Nairobi:20250320T203000
DTSTAMP:20260527T183908
CREATED:20250611T192311Z
LAST-MODIFIED:20250622T142307Z
UID:38878-1742497200-1742502600@kesho-kenya.org
SUMMARY:Metastatic Colorectal Cancer
DESCRIPTION:Moderator: Dr Alex Muturi \nSpeakers & Topics: \n\nProf Olusegun Alatise: Surgical & Gastroenterology Perspectives in mCRC Management\nDr Andrew Odhiambo: First‑Line Therapy in mCRC – With or Without?\n\nGlobal and African Burden of CRC \n– CRC is the third most diagnosed cancer globally with an increasing burden in LMICs.\n– African patients show distinct molecular and clinical features\, including poor survival outcomes. \nPrinciples of Metastatic CRC Management \n– Multidisciplinary approach is essential; cure remains possible in select patients.\n– Surgery for metastasis should be guided by tumor biology\, technical feasibility\, and patient fitness.\n– Synchronous vs metachronous disease influences treatment sequencing. \nImaging and Surgical Considerations \n– Triphasic CT\, MRI with contrast\, and PET scans are standard.\n– Resectability is based on liver function and margin clearance\, not number/size of lesions. \nSurgical and Interventional Therapies \n– Options: surgical resection\, ablation\, HAIP chemotherapy\, two-stage hepatectomy\, ALPPS\, SIRT.\n– Preoperative chemotherapy helps with tumor downsizing and biology assessment but may impair liver function. \nGenetic and Prognostic Scoring \n– CRS\, GAME\, MRS\, and MSI/BRAF/TP53 profiles aid in stratifying patients.\n– Even high-risk patients can achieve long-term survival with careful selection. \nNewer Modalities \n– Thermal ablation is effective for small (<3cm) liver lesions.\n– Liver transplant is under investigation for select liver-only\, unresectable CRC. \nPeritoneal Carcinomatosis \n– Cytoreductive surgery + HIPEC has survival benefits in low PCI scores.\n– PRODIGE 7\, COLOPEC\, and PROPHYLOCHIP trials show limited benefit of prophylactic HIPEC \nConclusion \n– Metastatic CRC is treatable; coordinated\, case-specific care improves survival.\n– Early detection and healthcare system strengthening in Africa are vital.
URL:https://kesho-kenya.org/event/metastatic-colorectal-cancer-3/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Metastatic-Colorectal-Cancer-e1749669731932.jpg
END:VEVENT
END:VCALENDAR